Aeterna Zentaris Reports Third Quarter 2022 Financial Results – Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 ...

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook – Continued advancement across diversified development pipeline – Company ended the quarter with $63.6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, May 11, 2022...